{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:45:26Z","timestamp":1786977926622,"version":"build-2736575974"},"reference-count":29,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Immunity Inflam &amp;amp; Disease"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We conducted this study to evaluate the impact of serum inflammatory markers and histopathological features on prognosis in metastatic hormone receptor positive breast cancer patients treated with first line CDK4\/6i (cyclin\u2010dependent kinase inhibitors).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>While serum markers are better indicators in triple\u2010negative and HER\u20102 positive breast cancers, the PFS (progression\u2010free survival) durations of NLR (neutrophil\/lymphocyte ratio), PLR (platelet\/lymphocyte ratio), and LMR (platelet\/lymphocyte ratios) in luminal A\u2013B group patients vary between studies.<\/jats:p>\n                    <jats:p>In our study investigated whether baseline NLR, PLR, and LMR have a predictive value for PFS in hormone\u2010positive metastatic breast cancer receiving CDK4\/6i.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and Methods<\/jats:title>\n                    <jats:p>The study included 111 patients with de novo metastasis or recurrence\/metastasis after adjuvant\/neo\u2010adjuvant treatment who received CDK\u20104\/6i as first\u2010line therapy. NLR, PLR, LMR, lymphocyte, neutrophil, and monocyte values were recorded from peripheral blood analyses before CDK\u20104\/6i treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      When the patient characteristics of patients were analyzed for progression\u2010free survival, no statistically significant differences were found between age, ECOG, grade, Ki\u201067 index, and menopause status. PFS was not significantly associated with NLR, PLR, and LMR values (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.87,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.51,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.22, respectively. In univariate analysis, among patients with LMR\u2009&gt;\u20093.48, ribociclib was associated with longer PFS than palbociclib. Multivariate analysis revealed that the luminal B molecular subtype was associated with significantly worse PFS compared to luminal A (23 vs. 43 months, respectively,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The prognostic impact of serum inflammatory markers in hormone receptor\u2013positive metastatic breast cancer is heterogeneous. Although no statistical significance was observed in our cohort, high LMR levels may provide predictive and prognostic value in treatment selection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/iid3.70442","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T04:59:12Z","timestamp":1776920352000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Predictive Role of Serum Inflammatory Markers in Metastatic Luminal A\/B Breast Cancers Receiving CDK\u20104\/6 Inhibitors Therapy"],"prefix":"10.1002","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2406-1946","authenticated-orcid":false,"given":"Nilufer","family":"Bulut","sequence":"first","affiliation":[{"name":"Department of Medical Oncology University of Health Sciences Istanbul Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9381-1934","authenticated-orcid":false,"given":"Tanju","family":"Kapagan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Basaksehir Cam and Sakura City Hospital Istanbul Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aykut","family":"Ozmen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Basaksehir Cam and Sakura City Hospital Istanbul Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gokmen Umut","family":"Erdem","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology University of Health Sciences Istanbul Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"e_1_2_15_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.09.019"},{"key":"e_1_2_15_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-023-01504-y"},{"key":"e_1_2_15_4_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1105587"},{"key":"e_1_2_15_5_1","doi-asserted-by":"publisher","DOI":"10.4103\/1742-6413.92550"},{"key":"e_1_2_15_6_1","doi-asserted-by":"publisher","DOI":"10.1159\/000503095"},{"key":"e_1_2_15_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104010"},{"key":"e_1_2_15_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/medicina55080461"},{"key":"e_1_2_15_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1378563"},{"key":"e_1_2_15_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.7949"},{"key":"e_1_2_15_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.03.082"},{"key":"e_1_2_15_12_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S227171"},{"key":"e_1_2_15_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01187-y"},{"key":"e_1_2_15_14_1","doi-asserted-by":"publisher","DOI":"10.3390\/genes12020159"},{"key":"e_1_2_15_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-022-01601-4"},{"key":"e_1_2_15_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/11782234211065148"},{"key":"e_1_2_15_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2025.104568"},{"key":"e_1_2_15_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad301"},{"key":"e_1_2_15_19_1","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2023.13684"},{"key":"e_1_2_15_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.28662"},{"key":"e_1_2_15_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4888-2"},{"key":"e_1_2_15_22_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S108419"},{"key":"e_1_2_15_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000001725"},{"key":"e_1_2_15_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2016.03.006"},{"key":"e_1_2_15_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy155"},{"key":"e_1_2_15_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.9909"},{"key":"e_1_2_15_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30292-4"},{"key":"e_1_2_15_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JGO.18.00173"},{"key":"e_1_2_15_29_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0019"},{"key":"e_1_2_15_30_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24108488"}],"container-title":["Immunity, Inflammation and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/iid3.70442","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/iid3.70442","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/iid3.70442","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T03:57:12Z","timestamp":1777435032000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/iid3.70442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1002\/iid3.70442"],"URL":"https:\/\/doi.org\/10.1002\/iid3.70442","archive":["Portico"],"relation":{},"ISSN":["2050-4527","2050-4527"],"issn-type":[{"value":"2050-4527","type":"print"},{"value":"2050-4527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"2025-07-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70442"}}